CHICAGO - Even in men and women with an optimal cardiovascular disease (CVD) risk factor profile, the lifetime risk estimate for CVD is greater than 30 percent, and is more than 50 percent for men and women overall, according to a study appearing in November 7 issue of JAMA, a theme issue on cardiovascular disease. The study is being released early online to coincide with the American Heart Association's Scientific Sessions.
"To date, there have been no published data on the lifetime risk for total CVD (including coronary heart disease [CHD], atherosclerotic and hemorrhagic stroke, congestive heart failure [CHF], and other CVD death)," according to background information in the article. "Estimates of lifetime risk for total CVD may provide projections of the future population burden of CVD and may assist in clinician-patient risk communication."
John T. Wilkins, M.D., M.S., of the Northwestern University Feinberg School of Medicine, Chicago, and colleagues conducted a study to estimate lifetime risk for total CVD in separate models for men and women overall and by aggregate risk factor burden at index ages of 45, 55, 65, and 75 years. The study consisted of a pooled survival analysis of data from 1964 through 2008 from five National Heart, Lung, and Blood Institute-funded community-based cohorts: Framingham Heart Study, Framingham Offspring Study, Atherosclerosis Risk in Communities Study, Chicago Heart Association Detection Project in Industry Study, and Cardiovascular Health Study. All participants were free of CVD at entry into the study with risk factor data (blood pressure [BP], total cholesterol [TC], diabetes, and smoking status) and total CVD outcome data. The primary outcome measure for the study was any total CVD event (including fatal and nonfatal coronary heart disease, all forms of stroke, congestive heart failure, and other CVD deaths).
Across all index ages, 1.7 percent to 7.9 percent of individuals were in the all optimal risk factor group. In contrast, more than 55 percent of individuals were in the 1 major or at least 2 major risk factor strata at all index ages. At some time during follow-up across all index age groups, approximately 30 percent to 35 percent of individuals experienced CVD events. The researchers found that at an index age of 45 years, overall lifetime risk estimates for total CVD through age 95 years were 60.3 percent for men, and 55.6 percent for women. Women had significantly lower lifetime risk estimates than men at all index ages.
At index ages 55 and 65 years, men and women with at least 1 elevated risk factor (BP, 140-149/90-99 mm Hg; or TC, 200-239 mg/dL; but no diabetes or smoking), 1 major risk factor, or at least 2 major risk factors (BP, 160/100 mm Hg or greater or receiving treatment; TC, 240 mg/dL or greater or receiving treatment; diabetes mellitus; or current smoking) had lifetime risk estimates to age 95 years that exceeded 50 percent. At an index age of 55 years, men with optimal risk factor profiles [BP, <120/80 mm Hg; TC, <180 mg/dL; and no smoking or diabetes] had remaining lifetime risks for total CVD that exceeded 40 percent and women had risks that approached 30 percent through 85 years of age.
Longer survival time free of total CVD was experienced by individuals with optimal risk factor levels when compared with participants with at least 2 major risk factors across all index ages. "For example, at an index age of 45 years, individuals with optimal risk factor profiles lived up to 14 years longer free of total CVD than individuals with at least 2 risk factors," the authors write.
The researchers note that "lifetime risks for total CVD were high regardless of index age, indicating that achieving older age free of total CVD does not guarantee escape from remaining lifetime risk for total CVD." They add that the finding of a substantial lifetime CVD risk even among individuals with an optimal risk factor profile highlights "the large public health burden and opportunities for prevention of total CVD."
(JAMA.2012;308:1795-1801. Available pre-embargo to the media at http://media.
Editor's Note: An author podcast for this study will be available on the journal website after the embargo lifts. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
To contact John T. Wilkins, M.D., M.S., call Erin White at 847-491-4888 or email firstname.lastname@example.org.